A coagulation blood test is used to measure and determine the bloods ability to clot and how fast it takes to clot, indicating the presence of lupus anticoagulant in the blood. An Enzyme-Linked ImmunoSorbent Assay (ELISA) test is done to detect anticardiolipin antibodies presence in the blood. Individuals with CAPS often exhibit a positive test to antilipid antibodies, typically IgG. Patients with high aPL(positive antiphospholipid antibodies) must have microthrombosis in multiple organs to definitively be diagnosed with CAPS— a high antilipid antibody count is not sufficient enough for diagnosis. To be diagnosed with CAPS, a patient must have three or more new organ thromboses developing within less than a week, and a biopsy must be later performed testing for microthrombosis in order to accurately diagnose the patient with ‘definite CAPS’. If the patient has two or less new organ thromboses within a week but a biopsy still indicates the presence of microthrombosis, the patient is not considered to have CAPS. Positive test are often repeated due to the fact that antilipid antibodies can be present in the body for short stints due to infection or drug use. Along with that, individuals may or may not have a history of lupus or another connective tissue disease. Association with another disease such as lupus is called a secondary APS unless it includes the defining criteria for CAPS. Treatment
Treatments may involve the following steps:

Prevention includes the use of antibiotics for infection and parenteral anticoagulation for susceptible patients.
References
External links
"Tagraxofusp". Drug Information Portal. U.S. National Library of Medicine. "Tagraxofusp-erzs". NCI Drug Dictionary. National Cancer Institute. "Tagraxofusp-erzs". National Cancer Institute. 22 January 2019.